| pubmed-article:11428976 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11428976 | lifeskim:mentions | umls-concept:C0010825 | lld:lifeskim |
| pubmed-article:11428976 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11428976 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
| pubmed-article:11428976 | lifeskim:mentions | umls-concept:C0023911 | lld:lifeskim |
| pubmed-article:11428976 | lifeskim:mentions | umls-concept:C0001367 | lld:lifeskim |
| pubmed-article:11428976 | lifeskim:mentions | umls-concept:C0199176 | lld:lifeskim |
| pubmed-article:11428976 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
| pubmed-article:11428976 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11428976 | pubmed:dateCreated | 2001-6-28 | lld:pubmed |
| pubmed-article:11428976 | pubmed:abstractText | Cytomegalovirus (CMV) is still a major pathogen in liver transplantation (LTX). The clinical efficacy of prophylactic high-dose acyclovir therapy (800 mg qid) was assessed for the prevention of CMV infection and disease in liver recipients. Fifty-five patients were enrolled in a prospective, randomised, double-blind and placebo-controlled trial; 28 on acyclovir vs. 27 on placebo. The therapy was given for 12 weeks. The patients were followed for 24 weeks. CMV infection was diagnosed in 60% (16 on acyclovir, 17 on placebo) and CMV disease developed in 38% (7 on acyclovir, 14 on placebo) of the patients. The total mortality was 27% (6 on acyclovir, 10 on placebo). Acyclovir delayed 32% of the CMV infections and prevented 59% of the CMV disease cases which occurred in the placebo cohort. The time to CMV disease was significantly prolonged in patients on acyclovir as compared to patients on placebo (P=0.013). Adverse events included neurotoxicity which occurred in 5 cases in the acyclovir, but none in the placebo arm, and nephrotoxicity which was detected in 6 patients in the acyclovir and 5 in the placebo arm, respectively. We conclude that acyclovir prophylaxis significantly reduced the incidence of CMV disease, and delayed the onset of CMV infection in liver transplant patients. | lld:pubmed |
| pubmed-article:11428976 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11428976 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11428976 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11428976 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11428976 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11428976 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11428976 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11428976 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11428976 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11428976 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:11428976 | pubmed:issn | 1398-2273 | lld:pubmed |
| pubmed-article:11428976 | pubmed:author | pubmed-author:TydénGG | lld:pubmed |
| pubmed-article:11428976 | pubmed:author | pubmed-author:AnderssonJJ | lld:pubmed |
| pubmed-article:11428976 | pubmed:author | pubmed-author:EriczonB GBG | lld:pubmed |
| pubmed-article:11428976 | pubmed:author | pubmed-author:RumiantsevV... | lld:pubmed |
| pubmed-article:11428976 | pubmed:author | pubmed-author:Lewensohn-Fuc... | lld:pubmed |
| pubmed-article:11428976 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11428976 | pubmed:volume | 1 | lld:pubmed |
| pubmed-article:11428976 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11428976 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11428976 | pubmed:pagination | 89-97 | lld:pubmed |
| pubmed-article:11428976 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:meshHeading | pubmed-meshheading:11428976... | lld:pubmed |
| pubmed-article:11428976 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:11428976 | pubmed:articleTitle | High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients. | lld:pubmed |
| pubmed-article:11428976 | pubmed:affiliation | Division of Transplantation Surgery, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden. lisbeth.barkholt@impi.ki.se | lld:pubmed |
| pubmed-article:11428976 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11428976 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11428976 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:11428976 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:11428976 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:11428976 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
